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Abstract
Background The aim of this study was to evaluate the perfor-
mance of selected pediatric estimated glomerular filtration rate
(eGFR) equations in relation to the clinical management of
children after renal or heart transplantation or post-
chemotherapy treatment.
Methods This study was a retrospective cross-sectional anal-
ysis of 61 children whose glomerular function (GFR) had
been determined using a single-dose inulin clearance (iGFR)
method. Eight equations for estimating the GFR were evalu-
ated for bias, agreement, accuracy, and clinical stratification.
Results The outcome of all eight eGFR equations differed
from the value determined using the iGFR method, with the
mean bias ranging from −3.4 to 20.7 ml/min/1.73 m2 and
90 % accuracy ranging from 16 to 26 %. All eGFR equations
overestimated renal function in patients with decreased kidney
function as determined by the iGFR method and
underestimated renal function in patients with normal kidney
function. Consequently, based on the eGFR values, patients
with low GFR values according to the iGFR method were
staged in a less severe chronic kidney disease (CKD) category,
and patients with normal GFR values according to the iGFR
method were staged in a more severe CKD category. The
percentage of correctly classified patients ranged from 32.6
to 41.6 %.
Conclusions In our cohort we found the CKiDIII equation to
be the best alternative to calculating the GFR using the inulin
clearance method, closely followed by the Hoste and the re-
vised Grubb equations. The performances of all eight eGFR
equations assessed were moderate at best and only slightly
better than the easy-to-do bedside Schwartz equation.
Keywords Children . Estimated glomerular filtration rate .
Chronic kidney disease . Renal transplantation . Heart
transplantation . Chemotherapy . Schwartz equation
Introduction
The ideal reference method for defining glomerular filtration
rate (GFR) is measuring the clearance of a marker that is freely
filtered in the glomerulus, not metabolized, and not secreted
by or re-absorbed in the tubule. The gold standard for calcu-
lating the GFR is based on measuring blood levels or urine
excretion following a single injection or a steady state infusion
of an exogenous marker, such as iohexol, iothalamate, inulin,
or 51Cr-EDTA, from which the GFR can be calculated [1, 2].
However, these tests are burdensome and expensive, and thus
less feasible for routine clinical practice [3]. Consequently,
clinicians prefer the alternative, endogenous markers, mostly
with the use of serum creatinine-based formulas, validated
against reference methods. There are, however, a number of
limitations associated with creatinine-based methods, such as
the creatinine level being related to muscle mass, creatinine
being actively secreted by the proximal tubule in the case of
severe renal functional impairment, and creatinine being me-
tabolized extrarenally by intestinal bacteria [4–8].
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This has led to growing interest in alternative methods to
calculate the GFR, including the use of cystatin C, which was
introduced as a marker for glomerular filtration in 1985 [9].
Cystatin C is a 13.3-kDa molecule that is ubiquitously pro-
duced by all nucleated cells, freely filtered in the glomerulus,
and subsequently completely re-absorbed and degraded in the
proximal tubule [10]. The cystatin C production rate per cell is
relatively stable throughout life from 2 years of age, and it
thereby may be an attractive marker of GFR in both children
and adults [10, 11]. It has been described as an almost ideal
marker, with only few limitations, such as its extrarenal elim-
ination (though presumed to be negligible), its dose-
dependent correlation to the use of glucocorticoids, and the
influence of thyroid dysfunction or diabetes mellitus [12].
The considerable body of research which has focused on
the development and validation of equations for estimating
GFR using creatinine, cystatin C, or a combination of both
[13–23] has mainly involved cohorts with specific ranges of
age and kidney function. As a consequence, the outcomes of
these equations are hard to extrapolate to other populations.
In the study reported here, , we retrospectively compared
the performance of eight selected equations used to estimate
GFR, all published between 1999 and 2014 and based on
serum creatinine and/or cystatin C, with the GFR calculated
from a single-injection inulin clearance method, in a cohort of
children and adolescents after heart or kidney transplantation,
or post nephrotoxic treatment of a malignancy. We also
assessed the reliability of the different equations to predict
chronic kidney disease (CKD) classification and thereby the
clinical management of the individual patient.
Materials and methods
Patients and study design
This study is a retrospective, cross-sectional analysis of pa-
tients in whom the GFR was assessed by a single-dose inulin
clearance method (iGFR). In our tertiary pediatric nephrology
center, inulin clearance is a routine test for patients after renal
transplant, heart transplant or post nephrotoxic chemotherapy.
In renal transplant patients, iGFR is performed yearly in the
first 3 years after transplantation and every other year thereaf-
ter. In heart transplant patients, it is performed 1 year after
heart transplantation and in some cases pre-heart transplanta-
tion, while in some oncology patients it is performed at least 1
year after cessation of chemotherapy. Our patient cohort
consisted of only patients in whom serum creatinine, urea,
and cystatin C were measured concomitantly.
We first performed a PubMed literature search with the
MESH terms Binfant^, Bchild^, Badolescent^, Bglomerular fil-
tration rate^, Bcreatinine^, and Bcystatin C^, initially selecting
cystatin C- and/or creatinine-based GFR equations which had
been published during the last 20 years and developed in a
pediatric cohort. We then selected the equations in those stud-
ies that matched ours in terms of cohort age, range of GFR,
and biochemical analysis used. The criteria were: (1) creati-
nine measurement by enzymatic assay, (2) cystatin C mea-
surement by turbidimetric assay, and (3) the equation had to
be developed for use in a pediatric and adolescent cohort with
a range of renal function from severely decreased to normal.
Studies originally designed for adult cohorts, but whose ap-
plication was analyzed in pediatric patients, were also
included.
Biochemical analysis
All biochemical analyses were performed on a Hitachi ana-
lyzer (Roche Diagnostics GmbH, Penzberg, Germany).
Creatinine was measured using the Creatinine Plus version 2
enzymatic assay (Roche Diagnostics), with interassay coeffi-
cients of variation (CV) of 1.0 and 0.8 % at 85.7 and
370 μmol/l, respectively. Blood urea was measured using
the UREAL assay (Roche Diagnostics), with interassay CV
of 2.2 and 1.3 % at 6.88 and 23.7 μmol/l, respectively.
Cystatin C was measured using the Tina-quant cystatin C
assay (Roche Diagnostics), with interassay CV of 1.9 and
2.5 % at 1.08 and 4.61 mg/l, respectively. The inulin analysis
and subsequent GFR calculation were performed as described
by van Rossum et al. [24] with blood sampling at 10, 30, 90,
and 240 min after injection of 5000 mg/1.73 m2 polyfructosan
(Inutest 25 %; Fresenius, Linz, Austria). All patients had a
single cannula placed for the inulin (polyfructosan) injection,
which was thoroughly flushed prior to blood sampling. The
inulin clearance was calculated using MW/Pharm 3.5
(Mediware, Groningen, the Netherlands), a pharmacokinetic
computer program using a two-compartment model by
Bayesian analysis to calculate estimated GFR (eGFR). This
Bayesian analysis combines information from the population
pharmacokinetic parameters with information derived from
the actual individual concentrations of samples to estimate
the individual pharmacokinetic parameters. The calculation
is based on the following pharmacokinetic parameters: plasma
clearance of inulin, volume of distribution of the central com-
partment, intercompartmental clearance, volume of distribu-
tion of the peripheral compartment. Data on these pharmaco-
kinetic parameters are obtained from the continuous infusion
of inulin. The interassay CV for the inulin concentration were
6.9 and 1.9 % at 136 and 725 mg/l, respectively. An iGFR of
>120 ml/min/1.73 m2 was set at 120 ml/min/1.73 m2.
Statistical analysis
Patient data were collected from our hospital data storage unit
where patient laboratory results are stored. Statistical analyses
were performed with SPSS statistical software (version 22.0;
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IBM Corp., Armonk, NY) and Analyse-It for Excel ver. 3.91
(Analyse-It Software, Leeds, UK;Microsoft Corp., Redmond,
WA). The eGFR calculated with the different equations were
compared to the GFR calculated by inulin clearance (iGFR).
A repeated-measures analysis of variance (ANOVA) was used
to establish whether sequential measurements could serve as
individual data points. We used Bland–Altman difference plot
analysis to analyze agreement between iGFR and the eGFR
determined using the different eGFR equations. This analysis
results in a correlation between the two methods and limits of
agreement, comprised of systemic (bias) and random
(precision) error, where the limits of agreement can be used
as a measure of total error [25]. Accuracy was calculated as
follows: the difference between the iGFR and each of the eight
eGFR outcomes was expressed as a percentage of the iGFR.
To compare equations, we calculated the percentage of the
samples whose eGFR differed by ≤10 % (±10 %), ≤20 %
(±20 %), or ≤30 % (±30 %), resulting in an accuracy of 90,
80, or 70 %, respectively.
We also compared CKD staging based on the different
eGFR equations with that based on the iGFR. The National
Kidney Foundation Kidney Disease Outcomes Quality
Initiative (KDOQI) stages were applied, including the dis-
crimination between stage 3a and 3b, since the difference
between these stages can have consequences for treatment
and monitoring [26]. These stages are: stage 1, GFR >90 ml/
min/1.73 m2; stage 2, 60–89 ml/min/1.73 m2; stage 3a, 45–
59 ml/min/1.73 m2 stage 3b, 30–44 ml/min/1.73 m2; stage 4,
15–29 ml/min/1.73 m2; stage 5, <15 ml/min/1.73 m2. The
abilities of the different eGFR equations to assign the correct
CKD class were compared with a McNemar’s test, which is
effectively a chi-square test on a 6×6 contingency table, and
the Cohen’s Kappa (κ) was calculated as a measure of agree-
ment [27]. The κ coefficient indicates the proportion of agree-
ment over and above chance agreement, with a κ value of 1
indicating complete agreement and a κ value of 0 indicating
no agreement. The P value indicates whether the coefficient is
statistically significantly different from zero.
Results
Study subjects
From February 2009 up to January 2013, 90 inulin clearance
tests (iGFR range 13–178 ml/min/1.73 m2) had been per-
formed in 61 patients (age range 3.2–19.1 years). Forty-five
and eight patients had undergone renal transplantation (70
measurements) and heart transplantation (12 measurements),
respectively, two were pre-heart transplantation patients (2
measurements), and six patients (6 measurements) had a his-
tory of a malignancy (3 rhabdomyosarcoma, 2 Ewing sarco-
ma, 1 hepatoblastoma). Since our dataset contained sequential
measurements we performed a repeated measures ANOVA
analysis to test whether repeated measures would influence
the outcome of the analyses. The interactions between the
repeated measurements and eGFR outcome were not signifi-
cant (P=0.281). Descriptive characteristics of the study co-
hort are given in Table 1.
Table 1 Patient characteristics at
time of inulin glomerular filtration
rate measurement
Descriptive characteristics of patient cohort Values
Number of samples 90
Number of patients 61
Gender distribution of samples Male 53 (59 %)
Age (years) 12.5 (7.8–16.4)
Weight (kg) 39.7 (18.5)
Height (cm) 141.5 (23.3)
Post kidney transplant/post heart transplant/other NTX 70 (78 %)/HTX 12 (13 %)/other 8 (9 %)
Inulin GFR range (ml/min/1.73 m2) 13–120
Inulin GFR median (ml/min/1.73 m2) 74 (53–97)
CKD stage (number of measurements)
CKD stage 5 (<15 ml/min/1.73 m2) 1 (1 %)
CKD stage 4 (15–29 ml/min/1.73 m2) 9 (10 %)
CKD stage 3b (30–44 ml/min/1.73 m2) 12 (13 %)
CKD stage 3a (45–59 ml/min/1.73 m2) 23 (26 %)
CKD stage 2 (60–89 ml/min/1.73 m2) 21 (23 %)
CKD stage 1 (> 0 ml/min/1.73 m2) 24 (27 %)
Data are presented as a number (n) with/without the percentage in parenthesis, as appropriate, or as the median with the interquartile range (IQR) given in
parenthesis
NTX, Post kidney transplant; HTX, post heart transplant; GFR, glomerular filtration rate; CKD, chronic kidney disease
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Selection of eGFR equation
Our literature search identified 20 cystatin C- and/or
creatinine-based GFR formulas that had been developed or
validated in children (Table 2). Of these 20 studies, seven
(with 8 eGFR equations) met our criteria of comparable bio-
chemical analysis, cohort age, and GFR distribution: Schwartz
et al. (modified bedside and CKIDIII) [23], Zappitelli et al.
[31], Hoste et al. [29], Grubb et al. (original and revised) [21,
22], Filler et al. [33], and Bökenkamp et al. [19]. The
Schwartz modified bedside, Hoste, and Zappitelli equations
are creatinine based, the Grubb original and revised, Filler,
and Bökenkamp equations are cystatin C based, and the
Schwartz CKiDIII is both creatinine and cystatin C based.
eGFR equation performance
The Bland–Altman difference plot analysis of the iGFR and
the eGFRs from the eight equations is shown in Fig. 1, and the
bias and limit of agreement values are presented in Table 3.
The mean bias of the tested equations ranged from −3.4 to
20.7, with the Hoste [29] equation showing the lowest bias.
The original and revised Grubb [21, 22], Hoste [29], and
CKiDIII Schwartz [23] equations did not show a significant
bias (the 95% confidence interval of the bias did contain zero)
in contrast to the other equations. The smallest interval for
limits of agreement, and thereby the lowest total error, was
shown by the CKiDIII Schwartz equation [23], followed by
the Filler [33] and revised Grubb [22] equations. When we
analyzed the performance of the equations using only the data
from the renal transplant recipients, we saw a decrease in
mean bias, a narrowing of the limits of agreement, and an
increase in the coefficient of determination (Table 4).
The difference fit analysis showed that all equations result-
ed in an overestimation of GFR at low iGFR values and an
underestimation of GFR at high iGFR values. Although over-
estimation is significant in all equations, the effect size varied
from 27 (CKiDIII Schwartz [23]) to 47 ml/min/1.73 m2 (Filler
[33]). All equations showed a negative association between
the iGFR and the difference between eGFR and iGFR. The
CKiDIII Schwartz [23] equation resulted in the smallest inter-
val for limits of agreement and the highest percentage of sam-
ples within 70, 80, and 90 % accuracy (Table 5).
Clinical stratification by CKD class
Figure 2 shows per iGFR–CKD class the percentage of sam-
ples that were assigned to a certain CKD class based on the
eGFR. Overall, the eGFR equations resulted in underestima-
tion of CKD stage (overestimation of renal function) com-
pared with the iGFR for patients with decreased iGFR, while
the opposite was true for patients with normal GFR. In the
group of iGFR–CKD1, the equation of BökenkampTa
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performed best by correctly classifying 20 of 24 patients,
whereas the CKiDIII Schwartz equation correctly classified
only four of the 24 patients. The CKiDIII Schwartz equation
correctly classified 12 of 20 patients with iGFR–CKD2, but
seven patients were staged in a higher (worse) class. In the
iGFR–CKD3a and –CKD3b classes, the CKiDIII Schwartz
equation resulted in the highest number of correctly classified
patients, and in the iGFR–CKD4 group, the Hoste equation
resulted in the highest number of correctly classified patients
(3 of 9 patients). No results are shown for the iGFR–CKD5
class as only one patient fell into this category.
To test whether classification by the eGFR equation dif-
fered from that by iGFR we used a McNemar chi-square test.
All P values were <0.0001, showing that the eGFR deter-
mined by all of the equations assessed were significantly dif-
ferent from the iGFR. To test the agreement between the clas-
sifications we performed a Cohen’s κ analysis, the results of
which are presented in Table 6. This test showed that agree-
ment overall was poor to moderate. The highest κ value was
observed for the bedside Schwartz equation (0.255), suggest-
ing only moderate agreement at best with the CKD classifica-
tion based on iGFR.
Fig. 1 Bland–Altman difference plot analysis between glomerular
filtration rate determined by the inulin method (iGFR) and estimated
GFR (eGFR) as calculated using different equations. GFR is expressed
in units of ml/min/1.73 m2. Horizontal axisAverage iGFR and respective
eGFR values, solid linemean bias, broken lines 95% limits of agreement,
dotted lines p30 (line indicating 30 % difference between measurements
and average). For chronic kidney disease (CKD) classification, see text
(Statistical analysis section) and Table 1
Table 3 Bias and limits of agreement values of Bland–Altman difference plot analysisa between glomerular filtration rate (GFR) determined by the
inulin method and the estimated GFR calculated using the different equations
eGFR equations Bias (95 % CI) Lower LoA (95 % CI) Upper LoA (95 % CI) Coefficient of
determination R2
Bedside Schwartz [23] 10.0 (4.4–15.7) −42.8 (−52.5 to −33.2) 62.9 (53.2–72.5) 0.614
Zappitelli [31] 14.6 (8.7–20.6) −40.6 (−50.8 to −30.5) 69.9 (59.8–80.0) 0.615
Hoste [29] 1.9 (−3.4 to 7.1) −47.1 (−56.1 to −38.1) 50.9 (41.9–59.9) 0.622
Original Grubb [21] 7.0 (−0.1 to 14.1) −59.4 (−71.6 to −47.3) 73.4 (61.2–85.6) 0.538
Revised Grubb [22] 3.0 (−2.1 to 8.1) −44.9 (−53.7 to −36.1) 50.8 (42.1–59.6) 0.619
Filler [33] 14.2 (9.4–19.0) −30.8 (−39.0 to −22.5) 59.2 (51.0–67.5) 0.655
Bökenkamp [19] 20.7 (15.4–26.0) −29.2 (−38.3 to −20.0) 70.6 (61.4–79.7) 0.655
CKiDIII Schwartz [23] −3.4 (−8.1 to 1.3) −47.2 (−55.3 to −39.1) 40.5 (32.4–48.5) 0.671
LoA, limits of agreement; CI, confidence interval; iGFR, inulin-based GFR
aAnalysis on whole dataset, including renal, and heart transplant recipients, and oncology patients (61 patients, 90 measurements). Graphical represen-
tation is shown in Fig. 1
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Discussion
In this study we addressed the efficacy of eight different equa-
tions to estimate GFR based on serum concentrations of cre-
atinine and/or cystatin C compared to the GFR based on inulin
clearance in a pediatric cohort of 61 children who were
followed after kidney or heart transplantation or after nephro-
toxic chemotherapy. Even though the selected GFR equations
were matched to our study cohort in terms of age, the GFR
range, and the biochemical methods used, the results varied
widely, and none of the equations performed particularly well.
Even the best coefficient of determination was only R2=0.67,
which is verymodest given that eGFR and iGFR are supposed
to be measuring the same thing and, therefore, are expected to
be highly correlated.
Based on the limits of agreement, the CKiDIII Schwartz
[23] equation performed best with a LoA interval of 87.8. This
equation also showed the highest accuracy with 26, 44, and
64 % of samples differing by <10, <20, or <30 % from the
reference method (iGFR), respectively, followed by the Hoste
and revised Grubb equations.
With regard to bias the equation by Hoste et al. [29]
showed the lowest bias (1.9), followed by the revised
Grubb, CKiDIII, and original Grubb equations, with bias of
3.0, −3.4, and 7.0, respectively, all of which were not
significant.
Nehus et al. [35] and Bacchetta et al. [36] showed a much
better performance of the eGFR equations they investigated in
their respective studies, with up to 44 and 48% of the samples
within 90 % accuracy, respectively. This difference from our
results may be due to differences in the iGFR range: in the
studies of Bacchetta et al. [36] and Nehus et al. [35], the
normal range of the iGFR was 100 ± 32 ml/min/1.73 m2
[mean ± standard deviation (SD)] and 95 (76–110) ml/min/
1.73 m2 [median (interquartile range)]. Both values are con-
siderably higher than the iGFR in our cohort [69 (52–94) ml/
min/1.73 m2] [mean (±SD)]. The inclusion of adolescents in
our cohort, in contrast to the CKiDIII cohort, may have de-
creased the performance of the CKiDIII Schwartz, which in
the study of Nehus et al. [35] did perform better than in our
study. Therefore, the difference in renal function between the
study cohorts in these studies and our cohort likely explains
the difference in performance.
An interesting finding of our study is that those equations
which performed best analytically (CKiDIII, Hoste, and re-
vised Grubb equations) were not the equations which
Table 4 Bias and limits of agreement values of Bland–Altman difference plot analysisa between iGFR and eGFR calculated using different equations
eGFR equations Bias (95 % CI) Lower LoA (95 % CI) Upper LoA (95 % CI) Coefficient of determination R2
Bedside Schwartz [23] 6.8 (1.1–12.5) −39.8 (−49.6 to −30.1) 53.4 (43.7–63.2) 0.678
Zappitelli [31] 11.7 (5.8–17.6) −36.9 (−47.0 to −26.7) 60.3 ((50.1–70.4) 0.683
Hoste [29] −0.8 (−6.22 to 4.6) −45.4 (−54.8 to −36.1) 43.9 (34.5–53.2) 0.675
Original Grubb [21] 2.4 (−3.8 to 8.5) −48.2 (−58.8 to −37.7) 52.9 (42.4–63.5) 0.668
Revised Grubb [22] 1.0 (−3.9 to 5.9) −39.5 (−47.9 to −31.0) 41.4 (33.0–49.9) 0.727
Filler [33] 12.3 (7.6–17.0) −26.4 (−34.5 to −18.3) 51.0 (42.9–59.0) 0.756
Bökenkamp [19] 17.0 (12.1–21.8) −23.1 (−31.5 to 14.7) 57.0 (48.7–65.4) 0.756
CKiDIII Schwartz [23] −4.6 (−9.5 to 0.4) −45.3 (−53.8 to −36.8) 36.2 (27.7–44.7) 0.724
iGFR inulin-based glomerular filtration rate, eGFR estimated glomerular filtration rate
a Analysis on data obtained only from renal transplant recipients (45 patients, 70 measurements)
Table 5 Accuracy analysis
eGFR equations 70 % accuracy 80 % accuracy 90 % accuracy
Bedside Schwartz [23] 59 % 34 % 19 %
Zappitelli [31] 52 % 33 % 16 %
Hoste [29] 61 % 46 % 21 %
Original Grubb [21] 52 % 38 % 20 %
Revised Grubb [22] 61 % 44 % 21 %
Filler [33] 43 % 34 % 18 %
Bökenkamp [19] 42 % 33 % 19 %
CKIDIII Schwartz [23] 64 % 44 % 26 %
Values in table are the percentages of estimated glomerular filtration rate (eGFR) results per equation that differ by <30, <20, or <10 % from the inulin-
based glomerular filtration rate (iGFR), resulting in 70, 80, or 90 % accuracy, respectively
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performed best in terms of CKD classification. This can be
explained by the unequal distribution of the number of pa-
tients over the different CKD classes. When only patients in
CKD classes 3a, 3b, and 4 were analyzed, the CKiDIII, Hoste,
and revised Grubb equations successively had the highest
number of correctly classified patients.
In our study, we saw that there was a trend for all equations,
both cystatin C- and/or creat inine-based, toward
overestimating renal function at lower iGFR values and
underestimating it at higher iGFR values. This trend was also
reflected in CKD staging: when we used the eGFR to assign a
CKD stage to every patient we observed an overall tendency
to stage patients at a lower (better) class based on their eGFR
than on their iGFR. In contrast, in patients with a higher iGFR,
renal function will be underestimated, although this will not
affect CKD staging, as for most equations this point is ≥90. In
general practice, this overestimation of renal function and in-
correct CKD classification can cause delay in treatment, over-
dosage of medication, and/or inadequate follow up.
The mathematical manipulations in the eGFR equations
assessed could potentially explain the difference in perfor-
mance between them. In the equations based only on cystatin
C, the result of the cystatin C assay had a stronger effect on the
outcome of the original Grubb equation [21] than on that of
Fig. 2 Chronic kidney disease (CKD) classification of patients according
to estimated glomerular filtration rate (eGFR) calculated using the
different equations, sorted by inulin-based glomerular filtration rate
(iGFR)–CKD class. Black arrowheads highlights the correct eGFR
class for the iGFR. GFR is expressed in units of ml/min/1.73 m2. For
CKD classification, see text (Statistical analysis section) and Table 1
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the Filler equation [33]. In the revised Grubb equation [22],
age has become an exponential factor, whereas in the original
Grubb equation it was a dichotomous factor; this change pos-
sibly results in a better correlation to the iGFR. The CKiDIII
Schwartz equation [23] is very complex because apart from
including the height/creatinine ratio, serum cystatin C level,
and blood urea level, it also has height as a separate exponen-
tial factor and gender as a factor. By including so many pa-
rameters that influence the outcome of this equation, each
individual parameter has a smaller effect on the eGFR calcu-
lated using this formula than in a simpler equation. As a result,
such the CKiDIII Swartz equation would be more resistant to
aberrations in the parameters on an individual patient level,
which can explain why in our study it outperformed the other
equations. On the other hand, the simplicity of the bedside
Schwartz equation makes it a useful tool in daily practice.
The study by Hoste et al. [29] shows the importance of
height correction in eGFR, as was also highlighted by
Schwartz [37] and confirmed in studies by Rink et al. [38]
and de Souza et al. [39]. All of these studies show that height
correction is particularly relevant in adolescent patients. Our
study cohort included adolescents, but we did not analyze
specific adolescent and pre-adolescent equations. In these
mixed populations the use of height-dependent equations
can have additional value. Of the equations included in our
study, only the Schwartz bedside equation, the CKiDIII equa-
tion, and the Hoste equation use height in the calculation of
the eGFR.
The equations analyzed in this study were developed in
studies with patient cohorts with suspected or established re-
nal pathology. The cohort in our study also included patients
before and after heart transplantation or in their follow-up after
chemotherapy. The inclusion of a variety of patients may in-
fluence the outcome of the performance analysis. Comparing
the performance of the equations in these subgroups to that of
the whole study cohort would give more insight into the use of
these equations in specific patient groups. However, the sub-
groups of oncology and heart transplantation were very small
in our study, making statistical analysis unfeasible. Analysis
of only the renal transplant recipient data showed some im-
provement in performance for all equations. Consequently,
using these equations in patients suffering from renal pathol-
ogy will yield more reliable results than in other patient
groups.
Although much work has been done on pediatric equations
using creatinine and cystatin C as biomarkers, we found that in
our cohort the performance of such equations was modest at
best. Better methods, or better equations, are needed to im-
prove and harmonize this field.
Our study has two major strengths. First, we selected eGFR
equations from the literature that had been validated in a co-
hort comparable to our cohort in terms of age, GFR range, and
biochemical methods used. This ensured that only eGFR
equations were included that should perform best in our co-
hort. Second, we related the calculated eGFR to CKD staging,
which provided good insight in the clinical consequences of
implementing these eGFR equations in daily practice. To our
knowledge, this latter analysis has not been done previously
for pediatric equations.
One limitation needs to be addressed. We did not use the
new International Federation of Clinical Chemistry and
Laboratory Medicine (IFCC)-calibrated cystatin C assay.
The IFCC reference material was established in 2010. Until
recently, almost all studies in the literature have used a non-
IFCC calibrated cystatin C assay, as a result of which the
cystatin C results can be biased, which will affect the eGFR
equation that was developed. This bias can lead to inaccuracy
in some equations. An exception is a recently published mul-
ticenter study by Grubb et al. [22] in which different IFCC
standardized assays were used to determine a new (revised)
equation to calculate the eGFR from the cystatin C concentra-
tion in blood. The use of an IFCC calibrated Roche assay will
result in concentrations that are approximately 15 % lower
than those used in our earlier assays (internal communication
with Roche Diagnostics). As a result, the eGFR from the
Grubb 2014 equation will be 23 % higher. When we corrected
Table 6 Summary of chronic
kidney disease category analysis eGFR equations Percentage correctly classified samples Cohen’s kappa (κ) (95 % CI)
a
Bedside Schwartz [23] 41.6 0.255 (0.126–0.384)
Zappitelli [31] 40.4 0.230 (0.103–0.357)
Hoste [29] 34.8 0.176 (0.049–0.303)
Grubb original [21] 36.0 0.177 (0.052–0.302)
Grubb revised [22] 32.6 0.124 (−0.003 to 0.251)
Filler [33] 32.6 0.105 (−0.005 to 0.215)
Bokenkamp [19] 37.1 0.162 (0.046–0.278)
CKIDIII Schwartz [23] 36.0 0.152 (0.036–0.268)
Data are presented as the percentage of correctly classified samples in classes iGFR–CKD1 through to IGFR–CKD4 of all 89 samples in these groups
CKD chronic kidney disease, iGFR inulin-based glomerular filtration rate, eGFR estimated glomerular filtration rate
a Cohen’s kappa (κ) analysis of CKD was used to categorize eGFR results (CKD–eGFR) compared to the iGFR (CKD–iGFR)
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for the 15 % difference between our assay and the new IFCC-
calibrated assay we found a mean bias of 22.6. A recent study
by Eckfeldt et al. did not show a 15 % decrease, but rather a
3.3 % increase in cystatin C results when using the Roche
IFCC-calibrated assay, which corresponds with our findings
using the revised Grubb equation [40].
In conclusion, in our cohort of pediatric and adolescent
patients we found the CKiDIII equation to be the best alterna-
tive to the inulin clearance test, closely followed by the Hoste
and revised Grubb equations, although the performance of all
three equations was only moderate at best. All eight equations
assessed showed inconsistency throughout the range of iGFR,
overestimating renal function at low iGFR values and
underestimating renal function at high ones. Since for daily
monitoring of renal function and screening of patients most
equations may be too elaborate, the modified bedside
Schwartz equation remains an acceptable alternative to the
iGFR.
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